Navigation Links
Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
Date:11/29/2007

Biologists, chemists, clinicians from Harvard, Stanford, University of Washington, the Scripps Research Institute, and Massachusetts General

Hospital partner with top investor groups Technology bypasses current debate on ethical use of embryonic stem cells by using pharmaceutical medicines to modulate stem cells inside the body

and via the use of 'reprogrammed' adult stem cells

SEATTLE, Nov. 29 /PRNewswire/ -- A group of the nation's most respected leaders in stem cell biology today announced formation of Fate Therapeutics, a new biotechnology company developing drugs to control cell fate. Fate will harness the healing power of adult stem cells by using small molecule drugs to modulate cells in vivo (in the body) and by reprogramming mature adult cells into stem cells.

"Fate's approach is the dawn of a new day in medicine," said Dr. Ben Shapiro, retired Executive Vice President of Worldwide Basic Research, Merck Research Laboratories, and a member of Fate's Science Advisory Board.

"Revolutionary advances in stem cell research have shifted the entire debate. We are proving that adult stem cell proliferation and differentiation can be modulated in the human body, and we now have the ability to induce pluripotent stem cells from adult human tissue rather than relying on the use of stem cells derived from embryos."

The company expects to have a lead adult stem cell modulating drug, in a cancer-related indication, enter the clinic in 2008.

Fate Therapeutics' revolutionary platform is two-fold

The Fate platform focuses on both regenerative and reprogramming medicine. The Fate regenerative medicine platform involves developing drugs that awaken adult stem cells in the body to repair damaged cells and tissues. The Fate reprogramming medicine platform involves developing drugs to reprogram mature adult cells into stem cells which when differentiated can become healthy heart, bone, brain o
'/>"/>

SOURCE Fate Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and distributor ... other markets, announced today that it has closed on ... investors led by Novit L.P., an investment arm of ... the signing of a Securities Purchase Agreement under which ... a price per share of $1.00, resulting in a ...
(Date:7/22/2014)... Parsippany, NJ (PRWEB) July 22, 2014 ... analytical, precision, portable, and mechanical balances and scales, ... precision balances has won Laboratory Equipment magazine’s 2014 ... is the second consecutive year the Explorer was ... readers. The annual Readers’ Choice Awards celebrates “excellence ...
(Date:7/22/2014)... and SHENZHEN, China , July ... LTD, (BGI Tech), a subsidiary of BGI, the ... launch of a new human whole exome sequencing ... newly offered service includes in-depth bioinformatics analysis and ... until December 31, 2014. Complete ...
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central IRB ... Quick Step™ . The offering went live on July ... need for seamless study start-up with a large volume of ... 50 or more North American investigator sites, as well as ... of 80 or more. Qualifying studies may also enroll international ...
Breaking Biology Technology:CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3
... EUREKA Cluster dedicated to Smart Systems Integration, will be ... community on 14-17 June 2011 in Helsinki, Finland. The ... the creation of new consortia and new projects by ... discuss proposals. EURIPIDES, in close cooperation with VTT and ...
... 20, 2011 Harvest Technologies Corp. ( www.harvesttech.com ) ... sixty patient Heart Failure trial have been enrolled at ... trial is intended to evaluate the safety and clinical ... patients with Congestive Heart Failure (CHF) when using a ...
... full year as a public company, 2010, the biotechnology developer Divine ... and grew Q4 revenue by 88 percent over the previous Q4, ... $5.4 million, up by $1.9 million over the previous year. Fourth-quarter ... quarter of 2009. The maker of topical treatments for ...
Cached Biology Technology:Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE) 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 2Divine Skin Posts Record Sales for 2010: Up 55% Over 2009 3
(Date:7/22/2014)... 14, 2014, by lightning from a weather system that moved ... fires: Stokes Fire, Gold Hikes Fire, French Creek Fire and ... now one larger fire. The fires are burning in timber ... acres in size. The present fire situation continues to ... firefighter safety is the priority on the Carlton Complex fires. ...
(Date:7/22/2014)... for Health Policy and Economics have linked tighter ... rates for schizophrenic individuals. , The study comes ... health actually save money, when other costs are ... an extra approval step before tests or treatments ... called prior authorization is intended to encourage ...
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
Breaking Biology News(10 mins):Are state Medicaid policies sentencing people with mental illnesses to prison? 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3
... (RFRH) systems with mulches were first researched in the ... water availability and to increase crop production. In RFRH ... bare or mulched furrows serve as planting zones. The ... in many parts of the world as a means ...
... of 34 institutions in 15 countries contributing to the measurements ... network, InGOS. , The network focuses on providing accurate information ... for a more vigorous climate action. In order to ... of greenhouse gas emissions is essential and not only ...
... article in the New England Journal of Medicine ... B was able to convert severe hemophilia to moderate or ... Methods Editor for Human Gene Therapy and ... represents an important milestone and "demonstrates unequivocally that gene therapy ...
Cached Biology News:Improved rainwater harvesting system promising 2DTU is participating in a European network on measurement of greenhouse gases 2Commentary and podcast on landmark gene therapy clinical trial for hemophilia B 2